Benefits and Information on CBD

Barriers between pro-Cannabis MDs and the medical establishment are falling. Doctors who monitor cannabis use by patients were bursting with questions yesterday during a talk by Sean McAllister, PhD, who has been studying the anti-cancer effects of cannabinoids in the laboratory (on a grant from NIH and with a license from the DEA). The occasion was the winter meeting of the Society of Cannabis Clinicians. "That's a very good question," McAllister would say, and provide the answer, and tie it back into his main thread.

Pot-based prescription drug looks for FDA OK

SAN FRANCISCO—A quarter-century after the U.S. Food and Drug Administration approved the first prescription drugs based on the main psychoactive ingredient in marijuana, additional medicines derived from or inspired by the cannabis plant itself could soon be making their way to pharmacy shelves, according to drug companies, small biotech firms and university scientists.

A British company, GW Pharma, is in advanced clinical trials for the world's first pharmaceutical developed from raw marijuana instead of synthetic equivalents— a mouth spray it hopes to market in the U.S. as a treatment for cancer pain. And it hopes to see FDA approval by the end of 2013.
Sativex contains marijuana's two best known components—delta 9-THC and cannabidiol—and already has been approved in Canada, New Zealand and eight European countries for a different usage, relieving muscle spasms associated with multiple sclerosis.

Study Finds Long Term Marijuana Smoking Does Not Reduce Lung Function

By Lindsey Tanner
Smoking a joint once a week or a bit more apparently doesn’t harm the lungs, suggests a 20-year study that bolsters evidence that marijuana doesn’t do the kind of damage tobacco does.
The results, from one of the largest and longest studies on the health effects of marijuana, are hazier for heavy users — those who smoke two or more joints daily for several years. The data suggest that using marijuana that often might cause a decline in lung function, but there weren’t enough heavy users among the 5,000 young adults in the study to draw firm conclusions.

Non-Psychotropic Cannabinoid Is "Safe," "Well Tolerated" In Humans, Study Says

Thursday, 22 December 2011


"CBD is non-toxic ... and does not alter psychomotor or psychological functions"


Sao Paulo, Brazil: The administration of the non-psychotropic cannabis plant constituent cannabidiol (CBD) is "non-toxic" to healthy cells and is "well tolerated" in humans, according to review data published online in the scientific journal Current Drug Safety.

Investigators at the University of Sao Paulo, Clinical Hospital reviewed over 130 papers assessing the impact of CBD in humans and animals. Studies describing the effects of multiple cannabinoids or CBD extracts were excluded from the analysis.